Moderna is trading at $184.68, down 7.13% at 9:48 a.m. ET on October 27, 2026, as its decline appears to extend the selloff after Phase 3 melanoma-vaccine results: the Keytruda combination reduced recurrence-or-death risk by 42%, below 49% in the earlier study. - Investors had reportedly priced in very high expectations for the cancer program; some saw the data as insufficient to support broader platform hopes. - The stock fell sharply after late-stage results details leaked, then declined again on Friday and Monday.